PTO/SB/08A(04-07)

Modified form approved for use through 09/30/2007. OMB 651-0031

US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO	Complete if Known	
	Application Number	10/589,216
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	January 15, 2008
	First Named Inventor	Lloyd S. Gray
(Use as many sheets as necessary)	Group Art Unit	1642
	Examiner Name	Christopher Yaen
Sheet 1 of 1	Attorney Docket No: 1036.115US1	

US PATENT DOCUMENTS					
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate	

FOREIGN PATENT DOCUMENTS					
Examiner Initial *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T 1	
	WO-9929847A1	6/17/1999	Perez-Reyes, et al.		

	OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS	
Examiner Initial *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 1
	"Japanese Application Serial No. 2006-553243, Office Action mailed 08-03-10", 10 pgs	
	BERTOLESI, GABRIEL E., et al., "The Ca2+ Channel Antagonists Mibefradil and Pimozide Inhibit Cell Growth via Different Cytotoxic Mechanisms", Mol. Pharmacol. Vol. 62, No.2, (2002), 210-219	
	HEADY, TIFFANY N., et al., "Molecular Pharmacology of T-type Ca2+ Channels", Jpn. J. Pharmacol Vol. 85, (2001), 339-350	
	YUNKER, A M. R., et al., "Immunological Characterizations of T-Type Voltage Dependent Calcium Channel CAv3.1 (ALPHA1G) and CAv3.3 (ALPHA1I) Isoforms Reveal Differences in Their Localization, Expression, and Neural Development", Neuroscience Vol. 117, (2003), 321-335	

EXAMINER DATE CONSIDERED